Ahead of the announcement of our cell therapy pipeline and lead candidate, 糖心原创 CEO Mark Kotter spoke with Endpoints News.
The piece covers our lead cell therapy candidate for acute liver failure - bbHEP01 - and the wider cell therapy pipeline that was announced on 8 November. They also cover 辞辫迟颈-辞虫鈩� and the overall cell programming approach that we are taking to produce human cells that are consistent at scale for therapies.
